Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced

In EMPEROR-Reduced (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction), empagliflozin reduced cardiovascular death or heart failure (HF) hospitalization and total HF hospitalizations, and slowed the progressive decline in kidney function in patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zannad, Faiez, Ferreira, João Pedro, Pocock, Stuart J., Zeller, Cordula, Anker, Stefan D., Butler, Javed, Filippatos, Gerasimos, Hauske, Sibylle Jenny, Brueckmann, Martina, Pfarr, Egon, Schnee, Janet, Wanner, Christoph, Packer, Milton
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834910/
https://www.ncbi.nlm.nih.gov/pubmed/33095032
http://dx.doi.org/10.1161/CIRCULATIONAHA.120.051685

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834910/
https://www.ncbi.nlm.nih.gov/pubmed/33095032
http://dx.doi.org/10.1161/CIRCULATIONAHA.120.051685

Ejemplares similares